keyword
MENU ▼
Read by QxMD icon Read
search

methylphenidate adhd

keyword
https://www.readbyqxmd.com/read/29131677/methylphenidate-has-superior-efficacy-over-parent-child-interaction-therapy-for-preschool-children-with-disruptive-behaviors
#1
Lianne van der Veen-Mulders, Barbara J van den Hoofdakker, Maaike H Nauta, Paul Emmelkamp, Pieter J Hoekstra
OBJECTIVE: To compare the effectiveness between parent-child interaction therapy (PCIT) and methylphenidate in preschool children with attention-deficit/hyperactivity disorder (ADHD) symptoms and disruptive behaviors who had remaining significant behavior problems after previous behavioral parent training. METHODS: We included 35 preschool children, ranging in age between 3.4 and 6.0 years. Participants were randomized to PCIT (n = 18) or methylphenidate (n = 17)...
November 13, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29129558/time-and-psychostimulants-opposing-long-term-structural-effects-in-the-adult-adhd-brain-a-longitudinal-mr-study
#2
Clara Pretus, J Antoni Ramos-Quiroga, Vanessa Richarte, Montse Corrales, Marisol Picado, Susanna Carmona, Óscar Vilarroya
Long-term effects of psychostimulants such as methylphenidate on ADHD patients have been proved to be difficult to capture in cross-sectional studies comparing medicated and non-medicated samples and in longitudinal studies with children, with age-related maturational processes possibly confounding independent effects of medication. However, chronic psychostimulant administration at therapeutic doses has been proven to yield profound neuroadaptive changes in rodent models. Here, we present for the first time the effect of psychostimulant treatment on brain volumes in a sample of medication-naïve adult ADHD patients...
November 9, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29125594/cotempla-xr-odt-another-long-acting-methylphenidate-for-adhd
#3
(no author information available yet)
No abstract text is available yet for this article.
November 6, 2017: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/29122720/connectome-based-predictive-modeling-of-attention-comparing-different-functional-connectivity-features-and-prediction-methods-across-datasets
#4
Kwangsun Yoo, Monica D Rosenberg, Wei-Ting Hsu, Sheng Zhang, Chiang-Shan R Li, Dustin Scheinost, R Todd Constable, Marvin M Chun
Connectome-based predictive modeling (CPM; Finn et al., 2015; Shen et al., 2017) was recently developed to predict individual differences in traits and behaviors, including fluid intelligence (Finn et al., 2015) and sustained attention (Rosenberg et al., 2016a), from functional brain connectivity (FC) measured with fMRI. Here, using the CPM framework, we compared the predictive power of three different measures of FC (Pearson's correlation, accordance, and discordance) and two different prediction algorithms (linear and partial least square [PLS] regression) for attention function...
November 6, 2017: NeuroImage
https://www.readbyqxmd.com/read/29121517/suicide-risk-reduction-in-youths-with-attention-deficit-hyperactivity-disorder-prescribed-methylphenidate-a-taiwan-nationwide-population-based-cohort-study
#5
Sophie Hsin-Yi Liang, Yao-Hsu Yang, Ting-Yu Kuo, Yin-To Liao, Tzu-Chin Lin, Yena Lee, Roger S McIntyre, Brent A Kelsen, Tsu-Nai Wang, Vincent Chin-Hung Chen
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) youths have increased suicide risk. Nevertheless, the beneficial effects of methylphenidate (MPH) on suicide attempt have received relatively little attention. AIMS: To investigate the MPH usage and the risk of suicide attempt among ADHD youths. METHODS: We identified 84,898 youths less than 18 years old with ADHD diagnosis between 1997 and 2013 from National Health Insurance, and examined whether MPH use affected suicide attempt risk using Cox proportional-hazards models...
November 6, 2017: Research in Developmental Disabilities
https://www.readbyqxmd.com/read/29112657/placental-complications-associated-with-psychostimulant-use-in-pregnancy
#6
Jacqueline M Cohen, Sonia Hernández-Díaz, Brian T Bateman, Yoonyoung Park, Rishi J Desai, Kathryn J Gray, Elisabetta Patorno, Helen Mogun, Krista F Huybrechts
OBJECTIVE: To evaluate whether psychostimulants used to treat attention-deficit/hyperactivity disorder (ADHD) are associated with risk of adverse placental-associated pregnancy outcomes including preeclampsia, placental abruption, growth restriction, and preterm birth. METHODS: We designed a population-based cohort study in which we examined a cohort of pregnant women and their liveborn neonates enrolled in Medicaid from 2000 to 2010. Women who received amphetamine-dextroamphetamine or methylphenidate monotherapy in the first half of pregnancy were compared with unexposed women...
November 3, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29098969/-upward-trend-in-the-use-of-psychostimulants-by-adults
#7
L van der Koog, J van der Schans, M A Tjioe, J H J Bos, B J Bijker, E Hak, C C M Schuiling-Veninga
OBJECTIVE: To gain insight into the trends in the use of psychostimulants among adults. DESIGN: Retrospective database study. METHODS: We selected data on adults (≥ 18 years) who had had a minimum of 2 prescriptions for a psychostimulant drug within 1 year from IADB.nl, a Netherlands database of filled prescriptions (59 public pharmacies, approximately 600,000 patients). We calculated both the number of new users and the total number of users of psychostimulants per year in the period 2004-2014...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29098467/a-6-month-follow-up-of-an-rct-on-behavioral-and-neurocognitive-effects-of-neurofeedback-in-children-with-adhd
#8
Katleen Geladé, Tieme W P Janssen, Marleen Bink, Jos W R Twisk, Rosa van Mourik, Athanasios Maras, Jaap Oosterlaan
To assess the long-term effects of neurofeedback (NFB) in children with attention deficit hyperactivity disorder (ADHD), we compared behavioral and neurocognitive outcomes at a 6-month naturalistic follow-up of a randomized controlled trial on NFB, methylphenidate (MPH), and physical activity (PA). Ninety-two children with a DSM-IV-TR ADHD diagnosis, aged 7-13, receiving NFB (n = 33), MPH (n = 28), or PA (n = 31), were re-assessed 6-months after the interventions. NFB comprised theta/beta training on the vertex (cortical zero)...
November 2, 2017: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/29096908/using-task-performance-to-inform-treatment-planning-for-youth-with-adhd-a-systematic-review
#9
REVIEW
Stephen J Molitor, Joshua M Langberg
The role that neuropsychological task performance plays in the assessment of Attention-Deficit/Hyperactivity Disorder (ADHD) is currently ambiguous, and findings are mixed regarding whether tasks have validity for diagnosing the disorder. Irrespective of their validity for diagnosing ADHD, neuropsychological tasks could provide valuable information to mental health professionals if they can inform recommendations for treatment targets and modalities. Therefore, this review sought to synthesize the available evidence related to the use of neuropsychological task performance as a tool for informing treatment planning for youth with ADHD...
December 2017: Clinical Psychology Review
https://www.readbyqxmd.com/read/29090087/extended-release-methylphenidate-monotherapy-in-patients-with-comorbid-social-anxiety-disorder-and-adult-attention-deficit-hyperactivity-disorder-retrospective-case-series
#10
Ahmet Koyuncu, Fahri Çelebi, Erhan Ertekin, Burcu Ece Kök, Raşit Tükel
BACKGROUND: The relationship between social anxiety disorder (SAD) and attention-deficit/hyperactivity disorder (ADHD) is a subject which has recently become a topic of interest for research. METHODS: In this study, 20 patients with comorbid SAD and adult ADHD who were treated with extended-release methylphenidate monotherapy were evaluated retrospectively. RESULTS: Clinical response for both ADHD and SAD symptoms was observed in 17 of 20 patients...
November 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29073754/hiccup-due-to-aripiprazole-plus-methylphenidate-treatment-in-an-adolescent-with-attention-deficit-and-hyperactivity-disorder-and-conduct-disorder-a-case-report
#11
Meryem Ozlem Kutuk, Gulen Guler, Ali Evren Tufan, Ozgur Kutuk
Our case had hiccups arising in an adolescent with the attention deficit and hyperactivity disorder (ADHD) and conduct disorder (CD) after adding aripiprazole treatment to extended-release methylphenidate. Actually, antipsychotics are also used in the treatment of hiccups, but studies suggest that they can cause hiccups as well. Within 12 hours of taking 2.5 mg aripiprazole added to extended-release methylphenidate at a dose of 54 mg/day, 16-year-old boy began having hiccups in the morning, which lasted after 3-4 hours...
November 30, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29071470/the-challenge-of-pharmacotherapy-in-children-and-adolescents-with-epilepsy-adhd-comorbidity
#12
REVIEW
Alberto Verrotti, Romina Moavero, Gianvito Panzarino, Claudia Di Paolantonio, Renata Rizzo, Paolo Curatolo
Epilepsy is common in children and adolescents where its prevalence is 3.2-5.5/1000. About one-third of patients also have attention deficit hyperactivity/impulsivity disorder (ADHD). The possible relationship between epilepsy and ADHD is still unclear, and ADHD symptoms (such as inattention, hyperactivity, behavioral disturbances) are frequently considered as adverse effects of antiepileptic drugs (AEDs). The literature was searched for data on the behavioral effects of AEDs. Phenobarbital is the most frequently reported medication to induce symptoms of ADHD, followed by topiramate and valproic acid...
October 25, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29061363/impact-of-developmental-exposure-to-methylphenidate-on-rat-brain-s-immune-privilege-and-behavior-control-versus-adhd-model
#13
Vanessa Coelho-Santos, Filipa L Cardoso, Ricardo A Leitão, Carlos A Fontes-Ribeiro, Ana Paula Silva
Attention deficit hyperactivity disorder (ADHD) is the most prevalent childhood mental disorders that often persists into adulthood. Moreover, methylphenidate (MPH) is the mainstay of medical treatment for this disorder. Yet, not much is known about the neurobiological impact of MPH on control versus ADHD conditions, which is crucial to simultaneously clarify the misuse/abuse versus therapeutic use of this psychostimulant. In the present study, we applied biochemical and behavioral approaches to broadly explore the early-life chronic exposure of two different doses of MPH (1...
October 20, 2017: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/29061293/methylphenidate-gender-trends-in-adult-and-pediatric-populations-over-a-7year-period
#14
Carole Ehrhardt, Quentin Boucherie, Vanessa Pauly, David Braunstein, Eléonore Ronflé, Xavier Thirion, Elisabeth Frauger, Joelle Micallef
OBJECTIVE: Methylphenidate (MPH) is a prescription-stimulant medication which is authorized in France for two indications: attention-deficit hyperactivity disorder in children (aged≥6years) and narcolepsy in cases where modafinil is ineffective (for children and adults). MPH use has increased worldwide in the past 2 decades in children and adults. Different pharmacoepidemiological Europeans studies have described MPH patterns of use. To our knowledge, few pharmacoepidemiological studies have described MPH patterns of use in France...
July 21, 2017: Thérapie
https://www.readbyqxmd.com/read/29058689/deficiency-of-tumor-suppressor-ndrg2-leads-to-attention-deficit-and-hyperactive-behavior
#15
Yan Li, Anqi Yin, Xin Sun, Ming Zhang, Jianfang Zhang, Ping Wang, Rougang Xie, Wen Li, Ze Fan, Yuanyuan Zhu, Han Wang, Hailong Dong, Shengxi Wu, Lize Xiong
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent psychiatric disorder in children. Although an imbalance of excitatory and inhibitory inputs has been proposed as contributing to this disorder, the mechanisms underlying this highly heterogeneous disease remain largely unknown. Here, we show that N-myc downstream-regulated gene 2 (NDRG2) deficiency is involved in the development of ADHD in both mice and humans. Ndrg2-knockout (Ndrg2-/-) mice exhibited ADHD-like symptoms characterized by attention deficits, hyperactivity, impulsivity, and impaired memory...
October 23, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29052741/-regional-differences-of-adhd-diagnosis-rates-in-health-insurance-data-from-2005-to-2015-methodological-considerations-and-results
#16
REVIEW
Thomas G Grobe
BACKGROUND AND OBJECTIVES: Attention deficit hyperactivity disorders (ADHD) are among the most common mental disorders in children and adolescents. For a number of years there has been evidence of regional differences in Germany. This article provides current results on the frequency of diagnosis and treatment and also discusses methodological aspects. MATERIALS AND METHODS: The analysis is based on routine data of a statutory health insurance company including annual diagnoses and drug prescriptions from 2005 to 2015 of at least 1...
October 20, 2017: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
https://www.readbyqxmd.com/read/29052617/adhd-smoking-withdrawal-and-inhibitory-control-results-of-a-neuroimaging-study-with-methylphenidate-challenge
#17
Maggie M Sweitzer, Scott H Kollins, Rachel V Kozink, Matt Hallyburton, Joseph English, Merideth A Addicott, Jason A Oliver, F Joseph McClernon
Smoking withdrawal negatively impacts inhibitory control, and these effects are greater for smokers with pre-existing attention problems, such as attention deficit/hyperactivity disorder (ADHD). The current study preliminarily evaluated changes in inhibitory control-related behavior and brain activation during smoking withdrawal among smokers with ADHD. Moreover, we investigated the role of catecholamine transmission in these changes by examining effects of 40 mg methylphenidate (MPH) administration. Adult daily smokers with (n=17) and without (n=20) ADHD completed fMRI scanning under each of three conditions: (a) smoking as usual+placebo; (b) 24 hr smoking abstinence+placebo and (c) 24 hr smoking abstinence+MPH...
October 20, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29052031/do-pharmaceuticals-improve-driving-in-individuals-with-adhd-a-review-of-the-literature-and-evidence-for-clinical-practice
#18
REVIEW
Craig B H Surman, Ronna Fried, Lauren Rhodewalt, Heidi Boland
Attention-deficit/hyperactivity disorder (ADHD) is defined as a disorder of impaired attention and/or behavioral control. Studies suggest that the condition can dispose individuals to a higher risk of automobile accidents. ADHD symptoms respond to pharmacotherapy in a majority of uncomplicated cases. Evidence on how pharmacotherapies for ADHD impact driving behavior or outcomes could allow clinicians to support on-road safety rationally. We therefore undertook a review to identify the evidence base to date indicating positive or negative effects of pharmacotherapies on driving behavior in individuals with ADHD...
October 2017: CNS Drugs
https://www.readbyqxmd.com/read/29039979/single-dose-pharmacokinetics-of-hld200-a-delayed-release-and-extended-release-methylphenidate-formulation-in-healthy-adults-and-in-adolescents-and-children-with-attention-deficit-hyperactivity-disorder
#19
Ann Childress, Shailly Mehrotra, Jogarao Gobburu, Angus McLean, Norberto J DeSousa, Bev Incledon
OBJECTIVE: Current extended-release (ER) formulations of psychostimulants used for treatment of attention-deficit/hyperactivity disorder (ADHD) provide an extended duration of ADHD symptom control; however, the onset of efficacy can be protracted and variable, leaving the early morning untreated. The primary objective was to characterize the single-dose pharmacokinetics and tolerability of HLD200, an evening-dosed, delayed-release (DR) and ER formulation of methylphenidate (MPH), in healthy adults and in adolescents and children with ADHD...
October 17, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29034227/psychostimulants-as-cognitive-enhancers-in-adolescents-more-risk-than-reward
#20
REVIEW
Kimberly R Urban, Wen-Jun Gao
Methylphenidate and other psychostimulants, originally developed to treat attention deficit-hyperactivity disorder, are increasingly abused by healthy adolescents and adults seeking an advantage in scholastic performance and work productivity. However, how these drugs may affect cognitive performance, especially in the young brain, remains unclear. Here, we review recent literature and emphasize the risks of abuse of psychostimulants in healthy adolescents and young adults. We conclude that while the desire for cognitive enhancement, particularly with rising costs of education and increasingly competitive nature of scholarship programs, is unlikely to diminish in the near future, it is crucial for the scientific community to thoroughly examine the efficacy and safety of these stimulants in healthy populations across development...
2017: Frontiers in Public Health
keyword
keyword
116871
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"